Magseed is an effective non-inferior alternative to wire guidance (WGL) that enables intraoperative localisation of tumours during breast conserving surgery (BCS). The COVID-19 pandemic has necessitated a Magseed pathway in our hospital to enable patients to self-isolate preoperatively. Previous studies have not evaluated patient experience; thus, here we report the qualitative data on patients' perspectives regarding Magseed. A prospective service evaluation of BCS patients was conducted between 1st July 2020 and 1st December 2020 (Audit Committee Approval Registration No 410). Data was collected on patient demographics, tumour specification, and procedural outcomes. Qualitative results were obtained using binary outcomes and 10-point Likert scales. 41 women were included, with median age 62 years (IQR 53-69) and median BMI 27.3 kg/m2 (IQR 22.6-30.8). 29 patients had IDC, 5 had other invasive carcinomas, 4 had preinvasive disease, and 3 had benign lesions. 25 patients were ER+, 21 PR+, 3 HER2+, and 1 was triple negative. Median waiting time between insertion and operation for Magseed was 13 days (IQR 4-119). 11 patients had close margins, 6 of whom required re-operative intervention. 1 (2.4%) seed was misplaced, 4 (10%) found the procedure uncomfortable, and 2 (5%) had complications (1 difficult insertion, 1 developed pain). All excisions had successful retrieval. After an explanation of Magseed and WGL techniques, 43/49 (88%) patients said they preferred the Magseed approach. Magseed localisation methods are acceptable to staff and patients based on our prospective service evaluation. Magseed enables preoperative self-isolation in the era of Covid-19 in view of safer surgical outcomes.